Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bleeding disorder of unknown cause: an illustrated review on current practice, knowledge gaps, and future perspectives.
Monard ALL, Mussert CMA, van Duijl TT, Kruip MJHA, Henskens YMC, van den Biggelaar M, Schutgens REG, Schols SEM, Fijnvandraat KJ, Meijer K, den Exter PL, Nieuwenhuizen L, van Moort I, Baker RI, O'Donnell JS, Cnossen MH, Heubel-Moenen FCJI. Monard ALL, et al. Among authors: van duijl tt. Res Pract Thromb Haemost. 2024 Nov 13;8(8):102625. doi: 10.1016/j.rpth.2024.102625. eCollection 2024 Nov. Res Pract Thromb Haemost. 2024. PMID: 39687924 Free PMC article.
Variant mapping using mass spectrometry-based proteotyping as a diagnostic tool in von Willebrand disease.
Kreft IC, van Duijl TT, van Kwawegen C, Atiq F, Phan W, Schuller MBP, Boon-Spijker M, van der Zwaan C, Meijer AB, Hoogendijk AJ, Bierings R, Eikenboom JCJ, Leebeek FWG, van den Biggelaar M; Willebrand in the Netherlands (WiN) study group. Kreft IC, et al. Among authors: van duijl tt. J Thromb Haemost. 2024 Jul;22(7):1894-1908. doi: 10.1016/j.jtha.2024.04.011. Epub 2024 Apr 27. J Thromb Haemost. 2024. PMID: 38679335 Free article.
Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.
Janssen JM, Verheijen RB, van Duijl TT, Lin L, van den Heuvel MM, Beijnen JH, Steeghs N, van den Broek D, Huitema ADR, Dorlo TPC. Janssen JM, et al. Among authors: van duijl tt. Clin Transl Sci. 2022 Aug;15(8):1916-1925. doi: 10.1111/cts.13300. Epub 2022 Jun 30. Clin Transl Sci. 2022. PMID: 35775126 Free PMC article.
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
Verheijen RB, van Duijl TT, van den Heuvel MM, Vessies D, Muller M, Beijnen JH, Janssen JM, Schellens JHM, Steeghs N, van den Broek D, Huitema ADR. Verheijen RB, et al. Among authors: van duijl tt. Cancer Chemother Pharmacol. 2021 Feb;87(2):269-276. doi: 10.1007/s00280-021-04230-4. Epub 2021 Jan 23. Cancer Chemother Pharmacol. 2021. PMID: 33484280
12 results